Inhibition of platelet adhesion to collagen as a new target for antithrombotic drugs

Current Drug Targets - Cardiovascular and Haematological Disorders

Volumn 3, Issue 2, 2003, Pages 125-140

  Vanhoorelbeke, K ^a   Ulrichts, H ^a   Schoolmeester, A ^a   Deckmyn, H ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Antiplatelet agent; Antithrombotic; Glycoprotein Ib V IX; Glycoprotein VI; In vivo; Integrin 2 1; Von Willebrand factor

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AURINTRICARBOXYLIC ACID; COLLAGEN; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; GINKGOLIDE B; GLYCOPROTEIN; GLYCOPROTEIN IB; HIRUDIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; INTEGRIN; MONOCLONAL ANTIBODY; MONOCROTALINE; RECEPTOR SUBTYPE; RECOMBINANT PROTEIN; SNAKE VENOM; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOCYTE RECEPTOR; TRIFLAVIN; VERY LATE ACTIVATION ANTIGEN 2; VON WILLEBRAND FACTOR;

BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; HEMOSTASIS; HUMAN; IN VIVO STUDY; MODULATION; NONHUMAN; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SUBENDOTHELIUM; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOSIS;

ANIMALS; COLLAGEN; FIBRINOLYTIC AGENTS; HUMANS; INTEGRIN ALPHA2BETA1; PLATELET ADHESIVENESS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PLATELET MEMBRANE GLYCOPROTEINS; VON WILLEBRAND FACTOR;

EID: 0038780817     PISSN: 15680061     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568006033481500     Document Type: Review

References (130)

1. Cauwenberghs, N.; Vanhoorelbeke, K.; Vauterin, S.; Deckmyn, H. Structural determinants within platelet glycoprotein Ibalpha involved in its binding to von Willebrand factor. Platelets, 2000, 11, 373.
2. Kehrel, B. Platelet-collagen interactions. Semin. Thromb. Hemost., 1995, 21, 123.
3. Sixma, J.J.; Wester, J. The hemostatic plug. Semin. Hematol., 1977, 14, 265.
4. Rauterberg, J.; Jaeger, E.; Althaus, M. Collagens in atherosclerotic vessel wall lesions. Curr. Top. Pathol., 1993, 87, 163.
5. Savage, B.; Saldivar, E.; Ruggeri, Z.M. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell, 1996, 84, 289.
6. Santoro, S.A. Identification of a 160,000 dalton platelet membrane protein that mediates the initial divalent cation-dependent adhesion of platelets to collagen. Cell, 1986, 46, 913.
7. Kehrel, B.; Wierwille, S.; Clemetson, K.J.; Anders, O.; Steiner, M.; Knight, C.G.; Farndale, R.W.; Okuma, M.; Barnes, M.J. Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not. Blood, 1998, 91, 491.
8. Monnet, E.; Depraetere, H.; Legrand, C.; Deckmyn, H.; Fauvel-Lafeve, F. A monoclonal antibody to platelet type III collagen-binding protein (TIIICBP) binds to blood and vascular cells, and inhibits platelet vessel-wall interactions. Thromb. Haemost., 2001, 86, 694.
9. Monnet, E.; Fauvel-Lafeve, F. A new platelet receptor specific to type III collagen. Type III collagen-binding protein. J. Biol. Chem., 2000, 275, 10912.
10. Chiang, T.M. The role of protein phosphatases 1 and 2A in collagen-platelet interaction. Arch. Biochem. Biophys., 1993, 302, 56.
11. Moog, S.; Mangin, P.; Lenain, N.; Strassel, C.; Ravanat, C.; Schuhler, S.; Freund, M.; Santer, M.; Kahn, M.; Nieswandt, B.; Gachet, C.; Cazenave, J.P.; Lanza, F. Platelet glycoprotein V binds to collagen and participates in platelet adhesion and aggregation. Blood, 2001, 98, 1038.
12. Deckmyn, H.; Van Houtte, E.; Vermylen, J. Disturbed platelet aggregation to collagen associated with an antibody against an 85-to 90-Kd platelet glycoprotein in a patient with prolonged bleeding time. Blood, 1992, 79, 1466.
13. Phillips, D.R.; Charo, I.F.; Scarborough, R.M. GPIIb-IIIa: the responsive integrin. Cell, 1991, 65, 359.
14. Fuster, V.; Badimon, L.; Badimon, J.J.; Chesebro, J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N. Engl. J. Med, 1992, 326, 242.
15. Fingerle, J.; Johnson, R.; Clowes, A.W.; Majesky, M.W.; Reidy, M.A. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc. Natl. Acad Sci. USA, 1989, 86, 8412.
16. Moore, S.; Friedman, R.J.; Singal, D.P.; Gauldie, J.; Blajchman, M.A.; Roberts, R.S. Inhibition of injury induced thromboatherosclerotic lesions by anti-platelet serum in rabbits. Thromb. Haemost., 1976, 35, 70.
17. Lopez, J.A. The platelet glycoprotein Ib-IX complex. Blood Coagul. Fibrinolysis, 1994, 5, 97.
18. Vicente, V.; Houghten, R.A.; Ruggeri, Z.M. Identification of a site in the alpha chain of platelet glycoprotein Ib that participates in von Willebrand factor binding. J. Biol. Chem., 1990, 265, 274.
19. Cauwenberghs, N.; Vanhoorelbeke, K.; Vauterin, S.; Deckmyn, H. Structural determinants within platelet glycoprotein Ibalpha involved in its binding to von Willebrand factor. Platelets, 2000, 11, 373.
20. Huizinga, E.G.; Tsuji, S.; Romijn, R.A.; Schiphorst, M.E.; de Groot, P.G.; Sixma, J.J.; Gros, P. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science, 2002, 297, 1176.
21. Uff, S.; Clemetson, J.M.; Harrison, T.; Clemetson, K.J.; Emsley, J. Crystal Structure of the Platelet Glycoprotein Ibalpha N-terminal Domain Reveals an Unmasking Mechanism for Receptor Activation. J. Biol. Chem., 2002, 277, 35657.
22. Bernard, J. Sur une nouvelle variété de dystrophie thrombocytaire-hémorragipare congénitale. 1948, 24, 3217.
23. Nurden, A.T.; Caen, J.P. Specific roles for platelet surface glycoproteins in platelet function. Nature, 1975, 255, 720.
24. Lopez, J.A.; Andrews, R.K.; Afshar-Kharghan, V.; Berndt, M.C. Bernard-Soulier syndrome. Blood, 1998, 91, 4397.
25. Murata, M.; Furihata, K.; Ishida, F.; Russell, S.R.; Ware, J.; Ruggeri, Z.M. Genetic and structural characterization of an amino acid dimorphism in glycoprotein Ib alpha involved in platelet transfusion refractoriness. Blood, 1992, 79, 3086.
26. Ito, T.; Ishida, F.; Shimodaira, S.; Kitano, K. Polymorphisms of platelet membrane glycoprotein Ib alpha and plasma von Willebrand factor antigen in coronary artery disease. Int. J Hematol., 1999, 70, 47.
27. Sperr, W.R.; Huber, K.; Roden, M.; Janisiw, M.; Lang, T.; Graf, S.; Maurer, G.; Mayr, W.R.; Panzer, S. Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young central Europeans. Thromb. Res., 1998, 90, 117.
28. Murata, M.; Matsubara, Y.; Kawano, K.; Zama, T.; Aoki, N.; Yoshino, H.; Watanabe, G.; Ishikawa, K.; Ikeda, Y. Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation. Circulation, 1997, 96, 3281.
29. Sonoda, A.; Murata, M.; Ito, D.; Tanahashi, N.; Ohta, A.; Tada, Y.; Takeshita, E.; Yoshida, T.; Saito, I.; Yamamoto, M.; Ikeda, Y.; Fukuuchi, Y.; Watanabe, K. Association between platelet glycoprotein Ibalpha genotype and ischemic cerebrovascular disease. Stroke, 2000, 31, 493.
30. Reiner, A.P.; Kumar, P.N.; Schwartz, S.M.; Longstreth, W.T., Jr.; Pearce, R.M.; Rosendaal, F.R.; Psaty, B.M.; Siscovick, D.S. Genetic variants of platelet glycoprotein receptors and risk of stroke in young women. Stroke, 2000, 31, 1628.
31. Baker, R.I.; Eikelboom, J.; Lofthouse, E.; Staples, N.; Afshar-Kharghan, V.; Lopez, J.A.; Shen, Y.; Berndt, M.C.; Hankey, G. Platelet glycoprotein Ibalpha Kozak polymorphism is associated with an increased risk of ischemic stroke. Blood, 2001, 98, 36.
32. Mikkelsson, J.; Perola, M.; Penttila, A.; Karhunen, P.J. Platelet glycoprotein Ibalpha HPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death. Circulation, 2001, 104, 876.
33. Ware, J.; Russell, S.; Ruggeri, Z.M. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc. Natl. Acad. Sci. USA, 2000, 97, 2803.
34. Kahn, M.L.; Diacovo, T.G.; Bainton, D.F.; Lanza, F.; Trejo, J.; Coughlin, S.R. Glycoprotein V-deficient platelets have undiminished thrombin responsiveness and Do not exhibit a Bernard-Soulier phenotype. Blood, 1999, 94, 4112.
35. Ramakrishnan, V.; Reeves, P.S.; DeGuzman, F.; Deshpande, U.; Ministri-Madrid, K.; DuBridge, R.B.; Phillips, D.R. Increased thrombin responsiveness in platelets from mice lacking glycoprotein V. Proc. Natl. Acad. Sci. USA, 1999, 96, 13336.
36. Ni, H.; Ramakrishnan, V.; Ruggeri, Z.M.; Papalia, J.M.; Phillips, D.R.; Wagner, D.D. Increased thrombogenesis and embolus formation in mice lacking glycoprotein V. Blood, 2001, 98, 368.
37. Cadroy, Y.; Hanson, S.R.; Kelly, A.B.; Marzec, U.M.; Evatt, B.L.; Kunicki, T.J.; Montgomery, R.R.; Harker, L.A. Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. Blood, 1994, 83, 3218.
38. Cauwenberghs, N.; Meiring, M.; Vauterin, S.; van, W., V; Lamprecht, S.; Roodt, J.P.; Novak, L.; Harsfalvi, J.; Deckmyn, H.; Kotze, H.F. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 1347.
39. Becker, B.H.; Miller, J.L. Effects of an antiplatelet glycoprotein Ib antibody on hemostatic function in the guinea pig. Blood, 1989, 74, 690.
40. Miller, J.L.; Thiam-Cisse, M.; Drouet, L.O. Reduction in thrombus formation by PG-1 F(ab′)2, an anti-guinea pig platelet glycoprotein Ib monoclonal antibody. Arterioscler. Thromb., 1991, 11, 1231.
41. Wu, D.; Meiring, M.; Kotze, H.F.; Deckmyn, H.; Cauwenberghs, N. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 323.
42. Gralnick, H.R.; Williams, S.; McKeown, L.; Kramer, W.; Krutzsch, H.; Gorecki, M.; Pinet, A.; Garfinkel, L.I. A monomeric von Willebrand factor fragment, Leu-504--Lys-728, inhibits von Willebrand factor interaction with glycoprotein Ib-IX [corrected]. Proc. Natl. Acad Sci. USA, 1992, 89, 7880.
43. McGhie, A.I.; McNatt, J.; Ezov, N.; Cui, K.; Mower, L.K.; Hagay, Y.; Buja, L.M.; Garfinkel, L.I.; Gorecki, M.; Willerson, J.T. Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain. Circulation, 1994, 90, 2976.
44. Yao, S.K.; Ober, J.C.; Garfinkel, L.I.; Hagay, Y.; Ezov, N.; Ferguson, J.J.; Anderson, H.V.; Panet, A.; Gorecki, M.; Buja, L.M.; . Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs. Circulation, 1994, 89, 2822.
45. Azzam, K.; Garfinkel, L.I.; Bal dit, S.C.; Cisse, T.M.; Drouet, L. Antithrombotic effect of a recombinant von Willebrand factor, VCL, on nitrogen laser-induced thrombus formation in guinea pig mesenteric arteries. Thromb. Haemost., 1995, 73, 318.
46. Andre, P.; Hainaud, P.; Bal dit, S.C.; Garfinkel, L.I.; Caen, J.P.; Drouet, L.O. Relative involvement of GPIb/IX-vWF axis and GPIIb/IIIa in thrombus growth at high shear rates in the guinea pig. Arterioscler. Thromb. Vasc. Biol., 1997, 17, 919.
47. Chang, M.C.; Lin, H.K.; Peng, H.C.; Huang, T.F. Antithrombotic effect of crotalin, a platelet membrane glycoprotein Ib antagonist from venom of Crotalus atrox. Blood, 1998, 91, 1582.
48. Yeh, C.H.; Chang, M.C.; Peng, H.C.; Huang, T.F. Pharmacological characterization and antithrombotic effect of agkistin, a platelet glycoprotein Ib antagonist. Br. J. Pharmacol., 2001, 132, 843.
49. Sadler, J.E. Biochemistry and genetics of von Willebrand factor. Annu. Rev. Biochem., 1998, 67, 395.
50. Fujimura, Y.; Titani, K.; Holland, L.Z.; Russell, S.R.; Roberts, J.R.; Elder, J.H.; Ruggeri, Z.M.; Zimmerman, T.S. von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J. Biol. Chem., 1986, 261, 381.
51. Denis, C.V. Molecular and cellular biology of von Willebrand factor. Int. J. Hematol., 2002, 75, 3.
52. Hoylaerts, M.F.; Yamamoto, H.; Nuyts, K.; Vreys, I.; Deckmyn, H.; Vermylen, J. von Willebrand factor binds to native collagen VI primarily via its A1 domain. Biochem. J., 1997, 324 (Pt 1), 185.
53. Lankhof, H.; van Hoeij, M.; Schiphorst, M.E.; Bracke, M.; Wu, Y.P.; Ijsseldijk, M.J.; Vink, T.; de Groot, P.G.; Sixma, J.J. A3 domain is essential for interaction of von Willebrand factor with collagen type III. Thromb. Haemost., 1996, 75, 950.
54. Berliner, S.; Niiya, K.; Roberts, J.R.; Houghten, R.A.; Ruggeri, Z.M. Generation and characterization of peptide-specific antibodies that inhibit von Willebrand factor binding to glycoprotein IIb-IIIa without interacting with other adhesive molecules. Selectivity is conferred by Pro1743 and other amino acid residues adjacent to the sequence Arg1744- Gly1745-Asp1746. J. Biol. Chem., 1988, 263, 7500.
55. Sadler, J.E. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb. Haemost., 1994, 71, 520.
56. Ewenstein, B.M. Von Willebrand's disease. Annu. Rev. Med, 1997, 48, 525.
57. Denis, C.V.; Wagner, D.D. Insights from von Willebrand disease animal models. Cell Mol. Life Sci., 1999, 56, 977.
58. Andre, P.; Brouland, J.P.; Roussi, J.; Bonneau, M.; Pignaud, G.; Bal dit, S.C.; Hainaud, P.; Vaiman, M.; Drouet, L. Role of plasma and platelet von Willebrand factor in arterial thrombogenesis and hemostasis in the pig. Exp. Hematol., 1998, 26, 620.
59. Nichols, T.C.; Bellinger, D.A.; Tate, D.A.; Reddick, R.L.; Read, M.S.; Koch, G.G.; Brinkhous, K.M.; Griggs, T.R. von Willebrand factor and occlusive arterial thrombosis. A study in normal and von Willebrand's disease pigs with diet-induced hypercholesterolemia and atherosclerosis. Arteriosclerosis, 1990, 10, 449.
60. Fuster, V.; Badimon, L.; Badimon, J.J.; Ip, J.H.; Chesebro, J.H. The porcine model for the understanding of thrombogenesis and atherogenesis. Mayo Clin. Proc., 1991, 66, 818.
61. Denis, C.; Methia, N.; Frenette, P.S.; Rayburn, H.; Ullman-Cullere, M.; Hynes, R.O.; Wagner, D.D. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc. Natl. Acad. Sci. USA, 1998, 95, 9524.
62. Bellinger, D.A.; Nichols, T.C.; Read, M.S.; Reddick, R.L.; Lamb, M.A.; Brinkhous, K.M.; Evatt, B.L.; Griggs, T.R. Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor. Proc. Natl. Acad Sci. USA, 1987, 84, 8100.
63. Krupski, W.C.; Bass, A.; Cadroy, Y.; Kelly, A.B.; Harker, L.A.; Hanson, S.R. Antihemostatic and antithrombotic effects of monoclonal antibodies against von Willebrand factor in nonhuman primates. Surgery, 1992, 112, 433.
64. Cisse-Thiam, M.; Girma, J.P.; Meyer, D.; Drouet, L. [Inhibition of thrombus formation by anti-Willebrand monoclonal antibodies in the guinea pig]. Dakar Med., 1999, 44, 45.
65. Kageyama, S.; Yamamoto, H.; Nagano, M.; Arisaka, H.; Kayahara, T.; Yoshimoto, R. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Br. J. Pharmacol., 1997, 122, 165.
66. Yamamoto, H.; Vreys, I.; Stassen, J.M.; Yoshimoto, R.; Vermylen, J.; Hoylaerts, M.F. Antagonism of vWF inhibits both injury induced arterial and venous thrombosis in the hamster. Thromb. Haemost., 1998, 79, 202.
67. Kageyama, S.; Yamamoto, H.; Nakazawa, H.; Yoshimoto, R. Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb. Res., 2001, 101, 395.
68. Kageyama, S.; Yamamoto, H.; Nakazawa, H.; Matsushita, J.; Kouyama, T.; Gonsho, A.; Ikeda, Y.; Yoshimoto, R. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 187.
69. Kageyama, S.; Matsushita, J.; Yamamoto, H. Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis. Eur. J. Pharmacol., 2002, 443, 143.
70. Phillips, M.D.; Moake, J.L.; Nolasco, L.; Turner, N. Aurin tricarboxylic acid: a novel inhibitor of the association of von Willebrand factor and platelets. Blood, 1988, 72, 1898.
71. Girma, J.P.; Fressinaud, E.; Christoplic, O.; Rouault, C.; Obert, B.; Takahashi, Y.; Meyer, D. Aurin tricarboxylic acid inhibits platelet adhesion to collagen by binding to the 509-695 disulphide loop of von Willebrand factor and competing with glycoprotein Ib. Thromb. Haemost., 1992, 68, 707.
72. Weinstein, M.; Vosburgh, E.; Phillips, M.; Turner, N.; Chute-Rose, L.; Moake, J. Isolation from commercial aurintricarboxylic acid of the most effective polymeric inhibitors of von Willebrand factor interaction with platelet glycoprotein Ib. Comparison with other polyanionic and polyaromatic polymers. Blood, 1991, 78, 2291.
73. Strony, J.; Phillips, M.; Brands, D.; Moake, J.; Adelman, B. Aurintricarboxylic acid in a canine model of coronary artery thrombosis. Circulation, 1990, 81, 1106.
74. Kawasaki, T.; Kaku, S.; Kohinata, T.; Sakai, Y.; Taniuchi, Y.; Kawamura, K.; Yano, S.; Takenaka, T.; Fujimura, Y. Inhibition by aurintricarboxylic acid of von Willebrand factor binding to platelet GPIb, platelet retention, and thrombus formation in vivo. Am. J. Hematol., 1994, 47, 6.
75. Takiguchi, Y.; Shimazawa, M.; Nakashima, M. A comparative study of the antithrombotic effect of aurintricarboxylic acid on arterial thrombosis in rats and guinea pigs. Br. J. Pharmacol., 1996, 118, 1633.
76. Kinlough-Rathbone, R.L.; Packham, M.A. Unexpected effects of aurin tricarboxylic acid on human platelets. Thromb. Haemost., 1992, 68, 189.
77. Azzam, K.; Cisse-Thiam, M.; Drouet, L. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis. Thromb. Haemost., 1996, 75, 203.
78. Golino, P.; Ragni, M.; Cirillo, P.; Pascucci, I.; Ezekowitz, M.D.; Pawashe, A.; Scognamiglio, A.; Pace, L.; Guarino, A.; Chiariello, M. Aurintricarboxylic acid reduces platelet deposition in stenosed and endothelially injured rabbit carotid arteries more effectively than other antiplatelet interventions. Thromb. Haemost., 1995, 74, 974.
79. Hisamichi, N.; Kawasaki, T.; Suzuki, K.; Kaku, S.; Sakai, Y.; Taniuchi, Y.; Sato, K.; Inagaki, O.; Tomioka, K.; Yanagisawa, I.; Takenaka, T.; Yanagi, K.; Ohshima, N. Synergistic effect of aurintricarboxylic acid and triflavin in a photochemically induced thrombosis model in rats. Eur. J. Pharmacol., 1996, 312, 69.
80. Strony, J.; Song, A,; Rusterholtz, L.; Adelman, B. Aurintricarboxylic acid prevents acute rethrombosis in a canine model of arterial thrombosis. Arterioscler. Thromb. Vasc. Biol., 1995, 15, 359.
81. Samples, S.D.; Dubinsky, J.M. Aurintricarboxylic acid protects hippocampal neurons from glutamate excitotoxicity in vitro. J. Neurochem., 1993, 61, 382.
82. Haimsohn, M.; Beery, R.; Karasik, A.; Kanety, H.; Geier, A. Aurintricarboxylic acid induces a distinct activation of the IGF-I receptor signaling within MDA-231 cells. Endocrinology, 2002, 143, 837.
83. Wu, D.; Vanhoorelbeke, K.; Cauwenberghs, N.; Meiring, M.; Depraetere, H.; Kotze, H.F.; Deckmyn, H. Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood, 2002, 99, 3623.
84. Barnes, C.S.; Krafft, B.; Frech, M.; Hofmann, U.R.; Papendieck, A.; Dahlems, U.; Gellissen, G.; Hoylaerts, M.F. Production and characterization of saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion to collagen. Semin. Thromb. Hemost., 2001, 27, 337.
85. Cruz, C.P.; Eidt, J.; Drouilhet, J.; Brown, A.T.; Wang, Y.; Barnes, C.S.; Moursi, M.M. Saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion, decreases platelet aggregation and intimal hyperplasia in a rat carotid endarterectomy model. J. Vasc. Surg., 2001, 34, 724.
86. Zahger, D.; Fishbein, M.C.; Garfinkel, L.I.; Shall, P.K.; Forrester, J.S.; Regnstrom, J.; Yano, J.; Cercek, B. VCL, an antagonist of the platelet GPlb receptor, markedly inhibits platelet adhesion and intimal thickening after balloon injury in the rat. Circulation, 1995, 92, 1269.
87. Matsuno, H.; Kozawa, O.; Niwa, M.; Uematsu, T. Inhibition of von Willebrand factor binding to platelet GP lb by a fractionated aurintricarboxylic acid prevents restenosis after vascular injury in hamster carotid artery. Circulation, 1997, 96, 1299.
88. Matsuno, H.; Kozawa, O.; Niwa, M.; Tanabe, K.; Ichimaru, K.; Takiguchi, Y.; Yokota, M.; Hayashi, H.; Uematsu, T. Multiple inhibition of platelet activation by aurintricarboxylic acid prevents vascular stenosis after endothelial injury in hamster carotid artery. Thromb. Haemost., 1998, 79, 865.
89. Kageyama, S.; Yamamoto, H.; Yoshimoto, R. Anti-human von willebrand factor monoclonal antibody AJvW-2 prevents thrombus deposition and neointinia formation after balloon injury in guinea pigs. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2303.
90. Elices, M.J.; Hemler, M.E. The human integrin VLA-2 is a collagen receptor on some cells and a collagen/laminin receptor oil others. Proc. Natl. Acad Sci. USA, 1989, 86, 9906.
91. Kamata, T.; Takada, Y. Direct binding of collagen to the I domain of integrin alpha 2 beta 1 (VLA-2, CD49b/CD29) in a divalent cation-independent manner. J. Biol. Chem., 1994, 269, 26006.
92. Depraetere, H.; Wille, C.; Gansemans, Y.; Stanssens, P.; Lauwereys, M.; Baruch, D.; De Reys, S.; Deckrmyn, H. The integrin alpha 2 beta 1 (GPIa/IIa)-I-domain inhibits platelet-collagen interaction. Thromb. Haemost., 1997, 77, 981.
93. Knight, C.G.; Morton, L.F.; Peachey, A.R.; Tuckwell, D.S.; Farndale, R.W.; Barnes, M.J. The collagen-binding A-domains of integrins alpha(1)beta(1) and alpha(2)beta(1) recognize the same specific amino acid sequence, GFOGER, in native (triple-helical) collagens. J. Biol. Chem., 2000, 275, 35.
94. Emsley, J.; Knight, C.G.; Farndale, R.W.; Barnes, M.J.; Liddington, R.C. Structural basis of collagen recognition by integrin alpha2beta1. Cell, 2000, 101, 47.
95. Kainoh, M.; Ikeda, Y.; Nishio, S.; Nakadate, T. Glycoprotein Ia/IIa-mediated activation-dependent platelet adhesion to collagen. Thromb. Res., 1992, 65, 165.
96. Jung, S.M.; Moroi, M. Activation of the platelet collagen receptor integrin alpha(2)beta(1): its mechanism and participation in the physiological functions of platelets. Trends Cardiovasc. Med., 2000, 10, 285.
97. Nieuwenhuis, H.K.; Akkerman, J.W.; Houdijk, W.P.; Sixma, J.J. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature, 1985, 318, 470.
98. Kehrel, B.; Balleisen, L.; Kokott, R.; Mesters, R.; Stenzinger, W.; Clemetson, K.J.; van de, L.J. Deficiency of intact thrombospondin and membrane glycoprotein Ia in platelets with defective collagen-induced aggregation and spontaneous loss of disorder. Blood, 1988, 71, 1074.
99. Handa, M.; Watanabe, K.; Kawai, Y.; Kamata, T.; Koyama, T.; Nagai, H.; Ikeda, Y. Platelet unresponsiveness to collagen: involvement of glycoprotein Ia- IIa (alpha 2 beta 1 integrin) deficiency associated with a myeloproliferative disorder. Thromb. Haemost., 1995, 73, 521.
100. Deckmyn, H.; Chew, S.L.; Vermylen, J. Lack of platelet response to collagen associated with an autoantibody against glycoprotein Ia: a novel cause of acquired qualitative platelet dysfunction. Thromb. Haemost., 1990, 64, 74.
101. Kunicki, T.J.; Kritzik, M.; Annis, D.S.; Nugent, D.J. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood, 1997, 89, 1939.
102. Kunicki, T.J.; Orchekowski, R.; Annis, D.; Honda, Y. Variability of integrin alpha 2 beta 1 activity on human platelets. Blood, 1993, 82, 2693.
103. Di Paola, J.; Federici, A.B.; Mannucci, P.M.; Canciani, M.T.; Kritzik, M.; Kunicki, T.J.; Nugent, D. Low platelet alpha2beta1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood, 1999, 93, 3578.
104. Furihata, K.; Nugent, D.J.; Kunicki, T.J. Influence of Platelet Collagen Receptor Polymorphisms on Risk for Arterial Thrombosis. Arch. Pathol. Lab Med., 2002, 126, 305.
105. Kroll, H.; Gardemann, A.; Fechter, A.; Haberbosch, W.; Santoso, S. The impact of the glycoprotein Ia collagen receptor subunit A1648G gene polymorphism on coronary artery disease and acute myocardial infarction. Thromb. Haemost., 2000, 83, 392.
106. Holtkotter, O.; Nieswandt, B.; Smyth, N.; Muller, W.; Hafner, M.; Schulte, V.; Krieg, T.; Eckes, B. Integrin {alpha) 2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. J. Biol. Chem., 2002.
107. Nieswandt, B.; Brakebusch, C.; Bergmeier, W.; Schulte, V.; Bouvard, D.; Mokhtari-Nejad, R.; Lindhout, T.; Heemskerk, J.W.; Zirngibl, H.; Fassler, R. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J., 2001, 20, 2120.
108. Furihata, K.; Clemetson, K.J.; Deguchi, H.; Kunicki, T.J. Variation in human platelet glycoprotein VI content modulates glycoprotein VI-specific prothrombinase activity. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 1857.
109. Lagrue-Lak-Hal, A.H.; Debili, N.; Kingbury, G.; Lecut, C.; Le Couedic, J.P.; Villeval, J.L.; Jandrot-Perrus, M.; Vainchenker, W. Expression and function of the collagen receptor GPVI during megakaryocyte maturation. J. Biol. Chem., 2001, 276, 15316.
110. Keller, P.M.; Schultz, L.D.; Condra, C.; Karczewski, J.; Connolly, T.M. An inhibitor of collagen-stimulated platelet activation from the salivary glands of the Haementeria officinalis leech. II. Cloning of the cDNA and expression. J. Biol. Chem., 1992, 267, 6899.
111. Connolly, T.M.; Jacobs, J.W.; Condra, C. An inhibitor of collagen-stimulated platelet activation from the salivary glands of the Haementeria officinalis leech. I. Identification, isolation, and characterization. J. Biol. Chem., 1992, 267, 6893.
112. Deckmyn, H.; Stassen, J.M.; Vreys, I.; Van Houtte, E.; Sawyer, R.T.; Vermylen, J. Calin from Hirudo medicinalis, an inhibitor of platelet adhesion to collagen, prevents platelet-rich thrombosis in hamsters. Blood, 1995, 85, 712.
113. Harsfalvi, J.; Stassen, J.M.; Hoylaerts, M.F.; Van Houtte, E.; Sawyer, R.T.; Vermylen, J.; Deckmyn, H. Calin from Hirudo medicinalis, an inhibitor of von Willebrand factor binding to collagen under static and flow conditions. Blood, 1995, 85, 705.
114. Depraetere, H.; Kerekes, A.; Deckmyn, H. The collagen-binding leech products rLAPP and calin prevent both von Willebrand factor and alpha2beta1(GPIa/IIa)-I-domain binding to collagen in a different manner. Thromb. Haemost., 1999, 82, 1160.
115. Schaffer, L.W.; Davidson, J.T.; Siegl, P.K.; Gould, R.J.; Nutt, R.F.; Brady, S.F.; Connolly, T.M. Recombinant leech antiplatelet protein prevents collagen-mediated platelet aggregation but not collagen graft thrombosis in baboons. Arterioscler. Thromb., 1993, 13, 1593.
116. Sugiyama, T.; Okuma, M.; Ushikubi, F.; Sensaki, S.; Kanaji, K.; Uchino, H. A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood, 1987, 69, 1712.
117. Moroi, M.; Jung, S.M.; Okuma, M.; Shinmyozu, K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin. Invest., 1989, 84, 1440.
118. Ryo, R.; Yoshida, A.; Sugano, W.; Yasunaga, M.; Nakayama, K.; Saigo, K.; Adachi, M.; Yamaguchi, N.; Okuma, M. Deficiency of P62, a putative collagen receptor, in platelets from a patient with defective collagen-induced platelet aggregation. Am. J. Hematol., 1992, 39, 25.
119. Arai, M.; Yamamoto, N.; Moroi, M.; Akamatsu, N.; Fukutake, K.; Tanoue, K. Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency. Br. J. Haematol., 1995, 89, 124.
120. Morton, L.F.; Hargreaves, P.G.; Farndale, R.W.; Young, R.D.; Barnes, M.J. Integrin alpha 2 beta 1-independent activation of platelets by simple collagen-like peptides: collagen tertiary (trip helical) and quaternary (polymeric) structures are sufficient alone for alpha 2 beta 1-independent platelet reactivity. Biochem. J., 1995, 306 (Pt 2), 337.
121. Asselin, J.; Knight, C.G.; Farndale, R.W.; Barnes, M.J.; Watson, S.P. Monomeric (glycine-prolinehydroxyproline) 1O repeat sequence is a partial agonist of the platelet collagen receptor glycoprotein VI. Biochem. J., 1999, 339 (Pt 2), 413.
122. Clemetson, J.M.; Polgar, J.; Magnenat, E.; Wells, T.N.; Clemetson, K.J. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors. J. Biol. Chem., 1999, 274, 29019.
123. Jandrot-Perrus, M.; Busfield, S.; Lagrue, A.H.; Xiong, X.; Debili, N.; Chickering, T.; Le Couedic, J.P.; Goodearl, A.; Dussault, B.; Fraser, C.; Vainchenker, W.; Villeval, J.L. Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a plate let-specific collagen receptor from the immunoglobulin superfamily. Blood, 2000, 96, 1798.
124. Ezumi, Y.; Uchiyama, T.; Takayama, H. Molecular cloning, genomic structure, chromosomal localization, and alternative splice forms of the platelet collagen receptor glycoprotein VI. Biochem. Biophys. Res. Commun., 2000, 277, 27.
125. Gross, B.S.; Melford, S.K.; Watson, S.P. Evidence that phospholipase C-gamma2 interacts with SLP-76, Syk, Lyn, LAT and the Fc receptor gamma-chain after stimulation of the collagen receptor glycoprotein VI in human platelets. Eur. J. Biochem., 1999, 263, 612.
126. Nieswandt, B.; Bergmeier, W.; Schulte, V.; Rackebrandt, K.; Gessner, J.E.; Zirngibl, H. Expression and function of the mouse collagen receptor glycoprotein VI is strictly dependent on its association with the FcRgamma chain. J. Biol. Chem., 2000, 275, 23998.
127. Konishi, H.; Katoh, Y.; Takaya, N.; Kashiwakura, Y.; Itoh, S.; Ra, C.; Daida, H. Platelets activated by collagen through immunoreceptor tyrosine-based activation motif play pivotal role in initiation and generation of neointimal hyperplasia after vascular injury. Circulation, 2002, 105, 912.
128. Nieswandt, B.; Schulte, V.; Bergmeier, W.; Mokhtari-Nejad, R.; Rackebrandt, K.; Cazenave, J.P.; Ohlmann, P.; Gachet, C.; Zirngibl, H. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J. Exp. Med., 2001, 193, 459.
129. Beviglia, L.; Poggi, A.; Rossi, C.; McLane, M.A.; Calabrese, R.; Scanziani, E.; Cook, J.J.; Niewiarowski, S. Mouse antithrombotic assay. Inhibition of platelet thromboembolism by disintegrins. Thromb. Res., 1993, 71, 301.
130. Ribba, A.S.; Loisel, I.; Lavergne, J.M.; Juhan-Vague, I.; Obert, B.; Cherel, G.; Meyer, D.; Girma, J.P. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb. Haemost., 2001, 86, 848.